European Leukemia Trial Registry
Trial: ALL GMALL Imatinib post SZT

More Details
Title pre-emptive vs. (MRD)-triggered administration of Imatinib after stem celltransplantation for Ph+/BCR-ABL+ALL
Scientific Title A randomized, multicenter phase III-study to compare the efficacy and safety of early pre-emptive versus minimal residual disease (MRD)-triggered administration of Imatinib Mesylate (STI571, Glivec) after stem cell transplantation for Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL).
Short Title ALL GMALL Imatinib post SZT
Trialgroup GMALL
Type of Trial multicentric, randomized
Disease Acute lymphoblastic leukemia(ALL) Stem cell transplantation
Acute lymphoblastic leukemia(ALL) Ph/BCR ABL +
Age >= 18 years
Status Closed
Start of Recruitment 01.06.2004
Leader Ottmann, Prof. Dr., Oliver
Contactperson

Study Physician
Bug, PD Dr. med., Gesine
Tel: +49 (0)69 6301 7369
Fax: +49 (0)69 6301 7463
Email: g.bug@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
Diagnostics

MRD-Analysis
Molekulargenetik-Labor der Med.Klinik II, Universitätsklinikum Frankfurt

STI-Level Measurement
Pharmakokinetisches Labor, Universitätsklinikum Dresden (HPLC-Labor 10D)

Cytogenetics
Tumorzytogenetik-Labor, Universität Düsseldorf

created 07.07.2006 Anja Hellenbrecht
changed 03.05.2018 Student Studienregister
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org